| Basics |
Mersana Therapeutics, Inc.
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.
|
| IPO Date: |
June 28, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$44.87M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.30 | 3.92%
|
| Avg Daily Range (30 D): |
$0.02 | 6.31%
|
| Avg Daily Range (90 D): |
$0.03 | 5.74%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.14M |
| Avg Daily Volume (30 D): |
2.46M |
| Avg Daily Volume (90 D): |
3.32M |
| Trade Size |
| Avg Trade Size (Sh.): |
170 |
| Avg Trade Size (Sh.) (30 D): |
415 |
| Avg Trade Size (Sh.) (90 D): |
447 |
| Institutional Trades |
| Total Inst.Trades: |
1,444 |
| Avg Inst. Trade: |
$1.69M |
| Avg Inst. Trade (30 D): |
$.54M |
| Avg Inst. Trade (90 D): |
$.54M |
| Avg Inst. Trade Volume: |
.23M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$.54M |
| Avg Closing Trade (90 D): |
$.54M |
| Avg Closing Volume: |
217.01K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.19
|
$-.09
|
|
Diluted EPS
|
|
$-.19
|
$-.09
|
|
Revenue
|
$
|
$ 2.75M
|
$ 12.6M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -24.12M
|
$ -11.5M
|
|
Operating Income / Loss
|
$
|
$ -24.51M
|
$ -12.07M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -5.46M
|
$ 19.87M
|
|
PE Ratio
|
|
|
|
|
